AusBiotech

Chimeric escalates CDH17 CAR-T trial to highest dose after strong safety and early activity signals February 12, 2026

Chimeric Therapeutics (ASX:CHM) has announced that its CHM CDH17 CAR-T program has advanced to Dose Level 3. This is the highest dose tier in the Phase 1 portion of its ongoing trial.

Patrys taps experienced biotech executive to drive clinical expansion February 12, 2026

The therapeutic antibody developer Patrys (ASX:PAB) has announced the appointment of Dr Samantha South as its new Chief Executive Officer, effective 16 February 2026.

Canine osteoarthritis study offers compelling translational evidence for PPS February 12, 2026

A new peer-reviewed study published in PLOS One has provided evidence that pentosan polysulfate sodium delivers sustained clinical, functional, and structural benefits in osteoarthritis, reinforcing its potential as a disease-modifying therapy.

Amplia expands U.S. footprint as AMPLICITY pancreatic cancer trial gains momentum February 12, 2026

Amplia Therapeutics (ASX:ATX) has taken a step forward in its clinical expansion strategy, announcing the opening of two U.S. trial sites for its AMPLICITY pancreatic cancer study.

CSL presses ahead with transformation as leadership changes February 12, 2026

CSL has reported a slip in first-half results for 2026, shaped by policy headwinds, restructuring charges and asset impairments, even as the company accelerates a wide-ranging transformation aimed at restoring growth and long-term value.

Immutep reaches midpoint in global Phase 3 lung cancer trial February 9, 2026

Immutep (ASX:IMM) has passed a key clinical milestone, achieving 50 per cent patient enrolment in its pivotal global Phase 3 trial evaluating a novel immunotherapy combination for first-line non-small cell lung cancer.

Memphasys fast-tracks Australian market entry with early TGA approval for Felix system February 9, 2026

Memphasys (ASX:MEM) has reached a major commercial milestone with the Therapeutic Goods Administration granting approval for its Felix System ahead of schedule, clearing the way for immediate sales and clinical deployment across Australia.

Algorae expands commercial footprint with new licensing deal February 9, 2026

Algorae Pharmaceuticals (ASX:1AI) has taken another step in building a diversified commercial medicines platform, finalising a new licensing and supply agreement that broadens its reach beyond oncology into cardiovascular and metabolic disease markets.

Arovella enters new chapter as board transitions follow clinical milestone February 9, 2026

Arovella Therapeutics (ASX:ALA) is entering a period of board renewal as the biotechnology company advances toward a critical clinical inflection point.

Molecule2Market appoints inaugural CEO to lead next phase of growth February 9, 2026

Australian contract research organisation Molecule2Market has appointed Dr Julie Ince-Demetriou as its first Chief Executive Officer, marking a pivotal moment in the company’s evolution as it enters a new phase of growth and operational scale.

Nuclear medicine sector argues for dedicated scheme to unlock cancer therapies February 5, 2026

Australia’s nuclear medicine sector is urging the Commonwealth to establish a dedicated national funding stream for radiopharmaceutical cancer therapies.

Cleo Diagnostics highlights urgent need for earlier ovarian cancer detection during awareness month February 5, 2026

Ovarian cancer remains notoriously difficult to diagnose at an early stage, with symptoms that are often vague, non-specific and easily mistaken for less serious conditions.

Most Read

CSL presses ahead with transformation as leadership changes

Patrys taps experienced biotech executive to drive clinical expansion

Amplia expands U.S. footprint as AMPLICITY pancreatic cancer trial gains momentum

Chimeric escalates CDH17 CAR-T trial to highest dose after strong safety and early activity signals

Canine osteoarthritis study offers compelling translational evidence for PPS

New Stories

Chimeric escalates CDH17 CAR-T trial to highest dose after strong safety and early activity signals

Patrys taps experienced biotech executive to drive clinical expansion

Canine osteoarthritis study offers compelling translational evidence for PPS

Amplia expands U.S. footprint as AMPLICITY pancreatic cancer trial gains momentum

CSL presses ahead with transformation as leadership changes

Immutep reaches midpoint in global Phase 3 lung cancer trial

Memphasys fast-tracks Australian market entry with early TGA approval for Felix system

Sign In

Most Read

CSL presses ahead with transformation as leadership changes

Patrys taps experienced biotech executive to drive clinical expansion

Amplia expands U.S. footprint as AMPLICITY pancreatic cancer trial gains momentum

Chimeric escalates CDH17 CAR-T trial to highest dose after strong safety and early activity signals

Canine osteoarthritis study offers compelling translational evidence for PPS

Follow Us

New Stories

Chimeric escalates CDH17 CAR-T trial to highest dose after strong safety and early activity signals

Patrys taps experienced biotech executive to drive clinical expansion

Canine osteoarthritis study offers compelling translational evidence for PPS

Amplia expands U.S. footprint as AMPLICITY pancreatic cancer trial gains momentum

CSL presses ahead with transformation as leadership changes

Immutep reaches midpoint in global Phase 3 lung cancer trial

Memphasys fast-tracks Australian market entry with early TGA approval for Felix system